DK1503759T3 - Substituerede quinoloncarboxylsyrer, deres derivater, virkningssted og anvendelser heraf - Google Patents
Substituerede quinoloncarboxylsyrer, deres derivater, virkningssted og anvendelser herafInfo
- Publication number
- DK1503759T3 DK1503759T3 DK03726824T DK03726824T DK1503759T3 DK 1503759 T3 DK1503759 T3 DK 1503759T3 DK 03726824 T DK03726824 T DK 03726824T DK 03726824 T DK03726824 T DK 03726824T DK 1503759 T3 DK1503759 T3 DK 1503759T3
- Authority
- DK
- Denmark
- Prior art keywords
- derivatives
- carboxylic acids
- sub
- site
- action
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38064102P | 2002-05-14 | 2002-05-14 | |
| PCT/US2003/014948 WO2003097564A2 (en) | 2002-05-14 | 2003-05-12 | Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1503759T3 true DK1503759T3 (da) | 2009-04-14 |
Family
ID=29549994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03726824T DK1503759T3 (da) | 2002-05-14 | 2003-05-12 | Substituerede quinoloncarboxylsyrer, deres derivater, virkningssted og anvendelser heraf |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7355047B2 (da) |
| EP (1) | EP1503759B1 (da) |
| JP (1) | JP4532263B2 (da) |
| KR (1) | KR20040107525A (da) |
| CN (1) | CN1652784A (da) |
| AT (1) | ATE417613T1 (da) |
| AU (1) | AU2003229043B2 (da) |
| BR (1) | BR0309965A (da) |
| CA (1) | CA2484308A1 (da) |
| DE (1) | DE60325347D1 (da) |
| DK (1) | DK1503759T3 (da) |
| ES (1) | ES2319176T3 (da) |
| HK (1) | HK1072905A1 (da) |
| IL (1) | IL164734A0 (da) |
| MX (1) | MXPA04011156A (da) |
| NZ (1) | NZ536061A (da) |
| WO (1) | WO2003097564A2 (da) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| JP4532263B2 (ja) * | 2002-05-14 | 2010-08-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換されたキノロンカルボン酸、その誘導体、作用の部位、およびその使用 |
| US7470706B2 (en) | 2004-01-31 | 2008-12-30 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| DE102004004971B3 (de) * | 2004-01-31 | 2005-09-15 | Aventis Pharma Deutschland Gmbh | Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel |
| UA85711C2 (ru) * | 2004-05-06 | 2009-02-25 | Зе Регентс Оф Зе Юниверсити Оф Калифорния | Замещенные енаминоны, их производные и их применение |
| WO2006002421A2 (en) * | 2004-06-24 | 2006-01-05 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| KR100938297B1 (ko) * | 2005-04-11 | 2010-01-22 | 에프. 호프만-라 로슈 아게 | (3,4-다이하이드로-퀴나졸린-2-일)-인단-1-일-아민 |
| JP4796624B2 (ja) * | 2005-05-04 | 2011-10-19 | エフ．ホフマン−ラ ロシュ アーゲー | ５−ｈｔ受容体に作用する（３，４−ジヒドロ−キナゾリン−２−イル）−（２−アリールオキシ−エチル）−アミン類 |
| EP1963271B1 (en) * | 2005-12-05 | 2010-07-28 | Merck Sharp & Dohme Corp. | Quinolone m1 receptor positive allosteric modulators |
| CA2634113A1 (en) * | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Quinolin- 4 - one derivatives as modulators of abc transporters |
| ES2624554T3 (es) | 2005-12-28 | 2017-07-14 | Vertex Pharmaceuticals Incorporated | Formas sólidas de n- [2,4 - bis (1,1 - dimetiletil) - 5 - hidroxifenil] - 1,4 - dihidro - 4 - oxoquinolina - 3 - carboxamida |
| US8063221B2 (en) * | 2006-03-13 | 2011-11-22 | Kyorin Pharmaceutical Co., Ltd. | Aminoquinolones as GSK-3 inhibitors |
| EP1886996A1 (en) * | 2006-08-10 | 2008-02-13 | Ferrer Internacional, S.A. | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions |
| MX2009001478A (es) * | 2006-08-10 | 2009-03-31 | Ferrer Int | Compuestos de 1h-quinolin-4-ona, procedimientos, usos y composiciones. |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| US8293737B2 (en) * | 2006-10-16 | 2012-10-23 | Bionomics Limited | Anxiolytic compounds |
| WO2009040377A2 (en) * | 2007-09-27 | 2009-04-02 | Ge Healthcare Limited | Imaging agents |
| WO2010047990A1 (en) * | 2008-10-23 | 2010-04-29 | Merck Sharp & Dohme Corp. | Fused heterocyclic m1 receptor positive allosteric modulators |
| CA2756031C (en) | 2009-03-20 | 2018-01-02 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| US20120093917A1 (en) * | 2009-04-02 | 2012-04-19 | Robert Hromas | Metnase and intnase inhibitors and their use in treating cancer |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| JP2014510065A (ja) | 2011-03-02 | 2014-04-24 | バイオノミックス リミテッド | 治療薬としての新規な小分子 |
| AU2012222869B2 (en) * | 2011-03-02 | 2015-08-13 | Bionomics Limited | Methods of treating a disease or condition of the central nervous system |
| WO2012151640A1 (en) | 2011-05-12 | 2012-11-15 | Bionomics Limited | Methods for preparing naphthyridines |
| BR112014021090B1 (pt) | 2012-02-27 | 2023-01-24 | Vertex Pharmaceuticals Incorporated | Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma |
| WO2016057730A1 (en) | 2014-10-07 | 2016-04-14 | Strohmeier Mark | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| CN107501107A (zh) * | 2017-09-26 | 2017-12-22 | 兰亚朝 | 喹诺酮药物的中间体合成方法 |
| CN111269131B (zh) * | 2020-03-12 | 2021-12-28 | 江苏飞宇医药科技股份有限公司 | 以三正丙胺为吸酸剂制备环丙乙酯胺化物的工艺 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1433774A (en) * | 1973-02-26 | 1976-04-28 | Allen & Hanburys Ltd | Heterocyclic compounds apparatus for conveying articles |
| JPS5715760B2 (da) * | 1974-06-11 | 1982-04-01 | ||
| US4390541A (en) | 1980-12-19 | 1983-06-28 | Lilly Industries Limited | Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease |
| US6248739B1 (en) * | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
| AU4818000A (en) * | 1999-05-06 | 2000-11-21 | Neurogen Corporation | Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands |
| GB0127349D0 (en) * | 2001-11-14 | 2002-01-02 | Glaxo Group Ltd | Macrolides |
| JP4532263B2 (ja) * | 2002-05-14 | 2010-08-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換されたキノロンカルボン酸、その誘導体、作用の部位、およびその使用 |
-
2003
- 2003-05-12 JP JP2004505299A patent/JP4532263B2/ja not_active Expired - Fee Related
- 2003-05-12 AU AU2003229043A patent/AU2003229043B2/en not_active Ceased
- 2003-05-12 CN CNA03810816XA patent/CN1652784A/zh active Pending
- 2003-05-12 MX MXPA04011156A patent/MXPA04011156A/es active IP Right Grant
- 2003-05-12 NZ NZ536061A patent/NZ536061A/en unknown
- 2003-05-12 CA CA002484308A patent/CA2484308A1/en not_active Abandoned
- 2003-05-12 AT AT03726824T patent/ATE417613T1/de not_active IP Right Cessation
- 2003-05-12 ES ES03726824T patent/ES2319176T3/es not_active Expired - Lifetime
- 2003-05-12 EP EP03726824A patent/EP1503759B1/en not_active Expired - Lifetime
- 2003-05-12 US US10/514,808 patent/US7355047B2/en not_active Expired - Fee Related
- 2003-05-12 DK DK03726824T patent/DK1503759T3/da active
- 2003-05-12 DE DE60325347T patent/DE60325347D1/de not_active Expired - Lifetime
- 2003-05-12 KR KR10-2004-7018340A patent/KR20040107525A/ko not_active Application Discontinuation
- 2003-05-12 BR BR0309965-2A patent/BR0309965A/pt not_active IP Right Cessation
- 2003-05-12 WO PCT/US2003/014948 patent/WO2003097564A2/en active Application Filing
-
2004
- 2004-10-20 IL IL16473404A patent/IL164734A0/xx unknown
-
2005
- 2005-08-02 HK HK05106618.4A patent/HK1072905A1/xx not_active IP Right Cessation
-
2008
- 2008-02-15 US US12/032,403 patent/US20080176897A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005535592A (ja) | 2005-11-24 |
| EP1503759B1 (en) | 2008-12-17 |
| WO2003097564A3 (en) | 2004-02-26 |
| JP4532263B2 (ja) | 2010-08-25 |
| AU2003229043B2 (en) | 2008-12-04 |
| DE60325347D1 (de) | 2009-01-29 |
| US20060178516A1 (en) | 2006-08-10 |
| ES2319176T3 (es) | 2009-05-05 |
| IL164734A0 (en) | 2005-12-18 |
| BR0309965A (pt) | 2005-03-01 |
| HK1072905A1 (en) | 2005-09-16 |
| WO2003097564A2 (en) | 2003-11-27 |
| EP1503759A4 (en) | 2006-02-15 |
| AU2003229043A1 (en) | 2003-12-02 |
| ATE417613T1 (de) | 2009-01-15 |
| MXPA04011156A (es) | 2005-02-17 |
| CN1652784A (zh) | 2005-08-10 |
| KR20040107525A (ko) | 2004-12-20 |
| US7355047B2 (en) | 2008-04-08 |
| US20080176897A1 (en) | 2008-07-24 |
| CA2484308A1 (en) | 2003-11-27 |
| EP1503759A2 (en) | 2005-02-09 |
| NZ536061A (en) | 2008-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1503759T3 (da) | Substituerede quinoloncarboxylsyrer, deres derivater, virkningssted og anvendelser heraf | |
| ATE543873T1 (de) | Herstellung von 3-hydroxypropionsäure mittels beta-alanine-pyruvat-aminotrransferase | |
| UA85711C2 (ru) | Замещенные енаминоны, их производные и их применение | |
| DK1805129T3 (da) | (Biphenyl-)carboxylsyrer og derivater deraf | |
| NO20035603D0 (no) | Fluorpyrrolidiner som dipeptidyl peptidase inhibitorer | |
| TR200103493T2 (tr) | Metaloproteaz önleyicileri | |
| NO20055370D0 (no) | Alfa-substituert karboksylsyre som PPAR modulatorer | |
| TW200621707A (en) | Substituted dipiperidine CCR2 antagonists cross reference to related applications | |
| ATE380175T1 (de) | Pyrrolidine als dipeptidyl peptidase inhibitoren | |
| IS8255A (is) | P38 kínasatálmar staðsettir á 5 hluta heteróhring | |
| NO20072767L (no) | Gabapentin prodrug vedvarende frigivelse orale doseringsformer | |
| HUP0401647A2 (hu) | Új béta-fenil-alfa-oxi-propionsav-származékok, előállítási eljárásaik és gyógyszerészetileg fontos vegyületek előállításánál történő felhasználásuk | |
| UA85597C2 (ru) | Четвертичные соли как антагонисты ccr2 | |
| NO20056161L (no) | Formuleringer for behandling av artrittilstander | |
| DK0678087T3 (da) | Forbindelser med selektiv aktivitet til retinoid-X-receptorer og metoder til modulering af processer medieret af retinoid-X | |
| DK0946176T3 (da) | Anvendelse af 7-(2-oxa-5,8-diazabicyclo[4.3.0]quinoloncarboxylsyre- og naphthydridoncarboxylsyrederivater til fremstilling af et lægemiddel til behandling af Helicobacter-pylori-infektioner og dermed associerede gastroduodenale sygdomme | |
| IS8231A (is) | Lyfjafræðilega gagnleg sölt karboxýlsýruafleiða | |
| AU2003293311A8 (en) | Secondary binding site of dipeptidyl peptidase iv (dp iv) | |
| FR2809595B1 (fr) | Derive laitier presentant une composition minerale et en acides amines selectivement modifiee, procedes pour sa fabrication, et utilisation. | |
| DK1871380T3 (da) | Kombineret anvendelse af prostaglandinforbindelse og protonpumpeinhibitor til behandlingen af gastrointestinale lidelser | |
| NO20033949D0 (no) | Sammensetning og fremgangsmåte til å behandle neoplastiske sykdommer assosiert med forhöyede matriks metalloproteinaseaktiviteter ved åbenytte katechinforbindelser | |
| DK1363876T3 (da) | Glucocorticoidreceptormodulatorer | |
| EA199900057A1 (ru) | Ингибиторы матриксных металлопротеиназ | |
| ATE421550T1 (de) | Inhibierung der kristallisation von kolophonium | |
| IS7489A (is) | (2-((2-alkoxý)-fenýl)-hringpent-1-enýl) arómatískkarbó- og heteróhringtengd sýra og afleiður |